Clinical experiences with bisphosphonate-associated osteonecrosis of the jaws: analysis of 21 cases

被引:28
作者
Junquera, Luis [1 ]
Gallego, Lorena [1 ]
Cuesta, Paz [2 ]
Pelaz, Alejandro [1 ]
Carlos de Vicente, Juan [1 ]
机构
[1] Univ Cent Hosp, Dept Oral & Maxillofacial Surg, Oviedo 33009, Spain
[2] Univ Cent Hosp, Dept Otorhinolaryngol, Oviedo 33009, Spain
关键词
RISK-FACTORS; SERUM CTX; PREVENTION; MARKER;
D O I
10.1016/j.amjoto.2008.07.014
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Purpose: The aim of the present study was to analyze the clinical presentation, risk factors, radiologic features, histopathologic and microbiological findings, treatment, and evolution of bisphosphonate-associated osteonecrosis of the jaws (BONJ). Methods: This study made a retrospective review of 21 patients who underwent treatment and diagnosis of BONJ during 2004 to 2007 in a tertiary health care center reference for 1,100,000 inhabitants. Results: The mean patient age at the time of presentation was 65.1 years. Of the 21 patients observed, 19 (90.4%) were receiving intravenous zoledronate. Of the 21 patients, 15 were treated with bisphosphonates for bone metastasis (71.4%), 5 for multiple myeloma (23.8%), and I for rheumatoid arthritis (4.7%). In 17 patients, the lesions occurred in the mandible. Fifteen patients had previous tooth extractions at the same site of bone necrosis. Conclusion: In our series, most patients improved with conservative surgical debridement. Prospective clinical trials would enable clinicians to make accurate judgments about risk, treatment, and outcome for patients with BONJ. (c) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:390 / 395
页数:6
相关论文
共 21 条
[11]   Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment [J].
Marx, RE ;
Sawatari, Y ;
Fortin, M ;
Broumand, V .
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2005, 63 (11) :1567-1575
[13]   Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment [J].
Marx, Robert E. ;
Cillo, Joseph E., Jr. ;
Ulloa, Juan J. .
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2007, 65 (12) :2397-2410
[14]   Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia [J].
Mavrokokki, Tony ;
Cheng, Andrew ;
Stein, Brien ;
Goss, Alastair .
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2007, 65 (03) :415-423
[15]  
Merigo Elisabetta, 2006, Acta Biomed, V77, P109
[16]   Serum levels of C-terminal telopeptide of type I collagen: a useful new marker of cortical bone loss in hemodialysis patients [J].
Okuno, S ;
Inaba, M ;
Kitatani, K ;
Ishimura, E ;
Yamakawa, T ;
Nishizawa, Y .
OSTEOPOROSIS INTERNATIONAL, 2005, 16 (05) :501-509
[17]   Serum CTX: A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy [J].
Rosen, HN ;
Moses, AC ;
Garber, J ;
Iloputaife, ID ;
Ross, DS ;
Lee, SL ;
Greenspan, SL .
CALCIFIED TISSUE INTERNATIONAL, 2000, 66 (02) :100-103
[18]   Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management [J].
Ruggiero, Salvatore L. ;
Fantasia, John ;
Carlson, Eric ;
Park, Hyde .
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY, 2006, 102 (04) :433-441
[19]   Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases [J].
Ruggiero, SL ;
Mehrotra, B ;
Rosenberg, TJ ;
Engroff, SL .
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2004, 62 (05) :527-534
[20]   Bisphosphonates and osteonecrosis of the jaw:: cause and effect or a post hoc fallacy? [J].
Van den Wyngaert, T. ;
Huizing, M. T. ;
Vermorken, J. B. .
ANNALS OF ONCOLOGY, 2006, 17 (08) :1197-1204